Asia-Pacific Medical Foods for Inborn Errors of Metabolism Market, By Products (Amino Acid, Glytactin with GMP Amino Acid-Modified Infant Formula With Iron, Low-Calcium/Vitamin D-Free Infant Formula With Iron, Low Protein Food and Others), Age Group (Infants, Weaning, Adolescent, Adults), Diseases (Phenylketonuria (PKU), Maple Syrup Urine Disease (MSUD), Homocystinuria, Methylmalonic Acidemia, Organic Acidurias, Propionic Acidemia, Isovaleric Acidemia, Disorders of Leucine Metabolism, Glutaric Acidemia Type I Renal Disease, Tyrosinemia Types I And II, Urea Cycle Disorders and Others), Forms (Powder, Liquids, Gels and Others) Packaging (Can, Jar, Packets, Bottle and Others), Distribution Channel (Retail Pharmacies, Hospital Pharmacies, Drugs Stores, Online Pharmacies and Others) – Industry Trends and Forecast to 2030.
Asia-Pacific Medical Foods for Inborn Errors of Metabolism Market Analysis and Size
Consumption of nutraceutical supplements and recommended medical food is rising relative to enzyme-based medicinal drugs. The trend away from medications and toward dietary supplements and medicinal foods is anticipated to change as a result of rising healthcare costs and customer preference for quick and easy illness management solutions. Medical food demand has increased over the previous year due to increased medical food expenditure and the introduction of novel products for new indications.
Data Bridge Market Research analyses that the medical foods for inborn errors of metabolism market value is USD 531.59 million in 2022, is expected to reach USD 1354.28 million by 2030, at a CAGR of 12.4% during the forecast period 2023 to 2030. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Asia-Pacific Medical Foods for Inborn Errors of Metabolism Market Scope and Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2023 to 2030
|
|
Base Year
|
2022
|
|
Historic Years
|
2021 (Customizable to 2015 - 2020)
|
|
Quantitative Units
|
Revenue in USD Million, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Products (Amino Acid, Glytactin with GMP Amino Acid-Modified Infant Formula With Iron, Low-Calcium/Vitamin D-Free Infant Formula With Iron, Low Protein Food and Others), Age Group (Infants, Weaning, Adolescent, Adults), Diseases (Phenylketonuria (PKU), Maple Syrup Urine Disease (MSUD), Homocystinuria, Methylmalonic Acidemia, Organic Acidurias, Propionic Acidemia, Isovaleric Acidemia, Disorders of Leucine Metabolism, Glutaric Acidemia Type I Renal Disease, Tyrosinemia Types I And II, Urea Cycle Disorders and Others), Forms (Powder, Liquids, Gels and Others) Packaging (Can, Jar, Packets, Bottle and Others), Distribution Channel (Retail Pharmacies, Hospital Pharmacies, Drugs Stores, Online Pharmacies and Others)
|
|
Countries Covered
|
China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC)
|
|
Market Players Covered
|
Nestlé Health Science (Switzerland), Nutricia (Netherlands), Solace Nutrition (U.S.), Abbott (U.S.), Mead Johnson & Company, LLC. (U.S.), BioMarin Pharmaceutical (U.S.), Ajinomoto Cambrooke, Inc. (U.S.), Poa Pharma (Sweden), PKU-MDmil (U.S.), Dr.Schar AG/SPA Primus Pharmaceuticals, Inc. (Italy), Pristine Organics Pvt. Ltd. (India), APR (U.S.), Ener-G foods, INC (U.S.) and Promin Metabolics (U.K.)
|
|
Market Opportunities
|
|
Market Definition
The term "medical food" was coined by the Orphan Drug Act, which was amended in 1988, and directed the FDA to develop regulations allowing such specialised food formulations to be used under medical supervision for the nutritional management of a disease or condition with medically established distinctive nutritional requirements. Some diseases known as inborn metabolic abnormalities which occurs when the body is unable to turn food into energy. Gene mutations result in decreased or absent synthesis of a certain enzyme that breaks down specific compounds. There are significant difficulties, because of the accumulation of harmful compounds. They are given particular diets, often known as medicinal meals, under the supervision of doctors in order to address these conditions.
Asia-Pacific Medical Foods for Inborn Errors of Metabolism Market Dynamics
Drivers
- Surge in preference for dietary supplements
Contrary to enzyme-based therapeutic drugs, nutritional supplements and foods that have been prescribed for medical purposes are growing in popularity. Rising healthcare expenses and consumer preference for rapid, low-cost and effective disease treatment approaches are most likely to blame for the trend away from pharmaceuticals and toward dietary supplements and therapeutic foods. The term "medical food" refers to a class of products that are used in the nutritional management of a number of disorders including inborn metabolic abnormalities, and that include certain nutrients to match the nutrient requirements of patients with particular illnesses. These specific factors are drive the market's expansion.
Opportunities
- Rising use of medical foods
The market is regulated by authoritative and medical foods are employed as therapy choices for inborn metabolic abnormalities. Between 85% and 90% of a person's dietary requirements are satisfied by the nutritional therapy for congenital metabolic abnormalities. These supplements are also almost completely side effect-free, making them safe for people of all ages. Private medical insurance in the US and a few other nations have recently started to provide reimbursement programmes for the use of specific medical meals. As a result, market expansion during the forecast period is anticipated to be driven by increased usage of medical food and nutrient supplements.
Restraints/Challenges
- High cost of medical foods
Medical foods are created for people who have difficulty swallowing, digesting, absorbing or metabolising regular foods or nutrients and whose nutritional management cannot be accomplished solely by altering their regular diet. Many health insurance policies in the U.S. do not adequately cover medical foods and without insurance many families cannot afford their high cost.
This medical foods for inborn errors of metabolism market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the medical foods for inborn errors of metabolism market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Recent developments
- In 2019, In the Netherlands, Nutricia established a sustainable facility. The large investment in the Nutricia Cuijk facility raised the production of specialized infant formula and the market's income.
- In 2022, Mead Johnson & Company, LLC announced that it had merged entirely with Reckitt Benckiser Group plc (RB). It was anticipated that the Mead Johnson brand and business would continue to grow to the effective innovation and marketing practices used by Reckitt Benckiser plc businesses.
Asia-Pacific Medical Foods for Inborn Errors of Metabolism Market Scope
The medical foods for inborn errors of metabolism market is segmented on the basis of products, age group, diseases, forms, packaging and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Products
- Amino Acid
- Glytactin with GMP Amino Acid-Modified Infant Formula with Iron
- Low-Calcium/Vitamin D-Free Infant Formula with Iron
- Low Protein Food
- Others
Age Group
- Infants
- Weaning
- Adolescent
- Adults
Diseases
- Phenylketonuria (PKU)
- Maple Syrup Urine Disease (MSUD)
- Homocystinuria
- Methylmalonic Acidemia
- Organic Acidurias
- Propionic Acidemia
- Isovaleric Acidemia
- Disorders of Leucine Metabolism
- Glutaric Acidemia Type I Renal Disease
- Tyrosinemia Types I and II
- Urea Cycle Disorders
- Others
Forms
- Powder
- Liquids
- Gels
- Others
Packaging
- Can
- Jar
- Packets
- Bottle
- Others
Distribution Channel
- Retail Pharmacies
- Hospital Pharmacies
- Drugs Stores
- Online Pharmacies
- Others
Medical Foods for Inborn Errors of Metabolism Market Regional Analysis/Insights
The medical foods for inborn errors of metabolism market is analyzed and market size insights and trends are provided by country, products, age group, diseases, forms, packaging and distribution channel as referenced above.
The countries covered in the medical foods for inborn errors of metabolism market report are China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC).
Germany is dominating the medical foods for inborn errors of metabolism market due to the increase in the number of new-born screening procedures and a rise in the number of medical food recommendations from doctors.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of Asia-Pacific brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Healthcare Infrastructure Growth Installed base and New Technology Penetration
The medical foods for inborn errors of metabolism market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipment, installed base of different kind of products for medical foods for inborn errors of metabolism market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on the medical foods for inborn errors of metabolism market. The data is available for historic period 2011-2021.
Competitive Landscape and Medical Foods for Inborn Errors of Metabolism Market Share Analysis
The medical foods for inborn errors of metabolism market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, Asia-Pacific presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to medical foods for inborn errors of metabolism market.
Some of the major players operating in the medical foods for inborn errors of metabolism market are:
- Nestlé Health Science (Switzerland)
- Nutricia (Netherlands)
- Solace Nutrition (U.S.)
- Abbott (U.S.)
- Mead Johnson & Company, LLC. (U.S.)
- BioMarin Pharmaceutical (U.S.)
- Ajinomoto Cambrooke, Inc. (U.S.)
- Poa Pharma (Sweden)
- PKU-MDmil (U.S.)
- Dr.Schar AG/SPA Primus Pharmaceuticals, Inc. (Italy)
- Pristine Organics Pvt. Ltd. (India)
- APR (U.S.)
- Ener-G Foods (U.S.)
- Promin Metabolics (U.K.)
SKU-